Using TcBuster™-M Transposase for Highly Efficient and Robust Delivery of Multicistronic Therapeutic Cargo in Immune Cells for Both RUO and Clinical Applications

The rapid evolution of genome engineering tools has fueled the development of immune and stem cell therapies, as both autologous and allogeneic therapeutics. However, viral-mediated therapies present challenges such as immunogenicity, cargo size limits, integration risks, manufacturing delays, and high costs.

This study explores how TcBuster-M (TcB-M), a commercially available non-viral transposase-based editing platform, addresses viral limitations to allow for faster generation of therapeutics to market.

Download this TcBuster scientific poster to gain insights into:

• The utilization of screening mutant libraries (containing >3 million variants) to generate a hyperactive mutant (TcB-M) with enhanced transposition rates
• TcB-M’s performance in transposing T cells, NK cells, and iPSCs with single and multicistronic cargos of varying sizes
• The comparative performance of TcB-M and other competitor transposases
• The efficacy of TcB-M engineered CAR-T and CAR-NK cell combination therapy in controlling tumor burden in a mouse model of human Burkitt’s lymphoma